TFEB (Transcription Factor EB)

The master transcriptional regulator of the autophagy–lysosomal pathway. TFEB activates the CLEAR (Coordinated Lysosomal Expression and Regulation) network — a gene-expression program encoding autophagy machinery, lysosomal biogenesis, and lipid catabolism genes. Its activity is gated by phosphorylation state: under nutrient-replete conditions, mTORC1 and ERK2/MAPK phosphorylate TFEB at Ser142 and Ser211 (rapamycin-resistant sites), sequestering it in the cytoplasm; upon starvation or lysosomal stress, dephosphorylation via calcineurin or mTORC1 inactivation releases TFEB for nuclear translocation. TFEB activity declines with age across tissues, contributing to disabled-macroautophagy and loss-of-proteostasis, and its restoration extends healthy lifespan in multiple model organisms.

Identity

UniProt: P19484 (TFEB_HUMAN)
NCBI Gene: 7942
HGNC symbol: TFEB
Mouse ortholog: Tfeb (one-to-one ortholog; highly conserved)
Length: 476 amino acids (canonical isoform)
Protein family: MITF/TFE family of basic helix-loop-helix leucine-zipper (bHLH-LZ) transcription factors
Paralogs: mitf, tfe3, tfec — share CLEAR-element binding capacity; tissue-expression profiles differ

Key functional domains

bHLH domain — mediates sequence-specific DNA binding to E-box-like CLEAR elements (consensus GTCACGTG) and homodimerization
Leucine-zipper — required for dimerization and stable DNA binding
N-terminal transactivation domain — recruits transcriptional co-activators
Nuclear localization signal (NLS) — masked by 14-3-3 binding when phosphorylated; exposed upon dephosphorylation
Regulatory phosphorylation cluster (N-terminal and mid-protein) — Ser142 and Ser211 are both mTORC1-regulated sites; per Settembre 2012 domain map (Fig. 3C), Ser142 is in the transactivation domain (TACD) region and Ser211 is positioned between the TACD and HLH domains; both are rapamycin-resistant mTORC1 substrates

The CLEAR network

Sardiello et al. 2009 identified a conserved palindromic 10-bp motif (the CLEAR element, GTCACGTGAC) in the promoters of known lysosomal genes and used it to predict a co-regulated gene network ¹. Most lysosomal genes showed coordinated transcriptional behavior regulated by TFEB; TFEB overexpression induced lysosomal biogenesis and enhanced degradation of complex molecules including mutant huntingtin ¹. The commonly cited figures of 471 candidate CLEAR-network genes (bioinformatic) and ~96 confirmed core genes (experimental) are from prior AI extraction attributed to this paper, but could not be verified from the abstract (paper is not_oa). These numbers may be accurate but should not be treated as confirmed until full-text access is obtained. unsourced no-fulltext-access Settembre et al. 2011 demonstrated that TFEB is not only a lysosomal biogenesis regulator but also directly activates expression of autophagy genes (including ULK1, BECN1, WIPI, SQSTM1, VPS11, VPS18, ATG9B among 11 significantly upregulated genes out of 51 analyzed, with a strong correlation r=0.42 to starvation-induced expression), establishing it as the master coordinator of the entire autophagy–lysosomal axis ². Importantly, Settembre 2011 identified ERK2 (MAPK pathway) as the principal kinase phosphorylating TFEB at Ser142 to control nuclear localization — rapamycin had little to no effect on TFEB localization in that paper; it was the ERK inhibitor that phenocopied starvation-induced TFEB nuclear accumulation ².

Partial resolution of gap from autophagy.md: The #gap/unsourced note on the “~500 CLEAR genes” figure is partially addressed here. The 471 predicted / 96 confirmed figures are the prior AI extraction’s numbers attributed to Sardiello 2009, but could not be independently verified in this pass because Sardiello 2009 is closed-access (not_oa) and the abstract does not contain these numbers. These figures remain #gap/unsourced pending full-text access. A genome-wide ChIP-seq characterization is in Palmieri 2011 (PMID 21358634), which should be cited for confirmed targets. unsourced no-fulltext-access

Key CLEAR-network target categories:

Category	Representative genes
Lysosomal hydrolases	CTSB, CTSD, GBA, HEXA, HEXB
Lysosomal membrane proteins	LAMP1, LAMP2, NPC1
Autophagy initiation	ULK1, BECN1 (BECLIN-1)
Autophagosome elongation / LC3	MAP1LC3A, MAP1LC3B, GABARAPL1
Autophagy cargo	SQSTM1 (p62)
Lipid catabolism / lipophagy	PNPLA2, LIPE
v-ATPase (lysosomal acidification)	ATP6V1A, ATP6V1B2

Regulation — the mTORC1 phospho-switch

Under nutrient-replete conditions, mTORC1 (anchored to the lysosomal surface via the Ragulator complex and rag-gtpases) directly phosphorylates TFEB. The two papers establishing this mechanism used different approaches and identified different primary sites:

Settembre et al. 2012 (EMBO J) demonstrates that Ser142 is a key mTORC1 substrate: a phospho-specific Ser142 antibody shows Torin1 (catalytic mTOR inhibitor) but not rapamycin abolishes S142 phosphorylation; in-vitro mTORC1 kinase assay confirms Ser142 as a direct substrate. The same paper identifies Ser211 as an additional mTORC1-regulated site via systematic serine-to-alanine mutagenesis — S211A causes constitutive nuclear TFEB localization, confirming S211 also controls localization ³.
Roczniak-Ferguson et al. 2012 (Sci Signal) independently demonstrates that mTORC1 phosphorylates TFEB at Ser211 → creates a 14-3-3 binding site → cytoplasmic retention ⁴. This paper focused on Ser211 as the principal 14-3-3 docking site.

Together, both sites (S142 and S211) are rapamycin-resistant mTORC1 substrates — Torin1 is required to abolish their phosphorylation. The dominant 14-3-3 docking site is Ser211 (per Roczniak-Ferguson); S142 also contributes to localization control (per Settembre 2012, where S142A drives nuclear accumulation).

Upon starvation, mTORC1 inactivates, S142 and S211 are dephosphorylated, TFEB is released from 14-3-3 → NLS exposed → nuclear translocation → transcriptional activation of the CLEAR network ³ ⁴.

Pharmacological mTORC1 inhibitors torin1 and torin2 drive TFEB nuclear translocation by preventing S142/S211 phosphorylation. Rapamycin is a partial and allosteric inhibitor: Settembre 2012 demonstrates that rapamycin (2.5 µM) caused only a partial molecular-weight shift and did not affect TFEB subcellular localization in the high-content assay, whereas Torin1 (EC50 ≈ 148 nM) and Torin2 (EC50 ≈ 1,666 nM) caused massive TFEB nuclear accumulation (the ERK inhibitor U0126 EC50 was ~80,000 nM and showed only partial effect) ³. Rapamycin is therefore a poor TFEB activator at doses routinely used (10 nM–10 µM) despite being an effective mTORC1 substrate inhibitor for other substrates — because S142 and S211 are rapamycin-resistant mTORC1 phosphosites. dose-response-unclear — the TFEB-specific effective dose-window for Torin1 vs rapalogs is not fully characterized across tissues in vivo.

mTOR-independent regulation — calcineurin / Ca²+ arm

Medina et al. 2015 identified a second, mTOR-independent regulatory arm ⁵. During lysosomal stress or starvation, lysosomal Ca²+ is released via mucolipin-1 (TRPML1, encoded by MCOLN1), which activates the phosphatase calcineurin (PP3CB). Calcineurin dephosphorylates TFEB → nuclear translocation, independently of mTOR activity ⁵. Genetic and pharmacological inhibition of calcineurin suppressed TFEB nuclear accumulation during starvation and exercise; calcineurin overexpression had the opposite effect; MCOLN1-mediated calcineurin activation was required for autophagy and lysosomal biogenesis induction ⁵. This Ca²+-calcineurin arm allows TFEB activation even under conditions where mTOR remains partially active (e.g., during some forms of cellular stress).

Note: The calmodulin intermediate (TRPML1 → Ca²+ → calmodulin → calcineurin) is commonly cited in review literature but could not be confirmed from the Medina 2015 abstract alone (paper is not_oa). The abstract states MCOLN1 activates calcineurin directly. Whether calmodulin is an explicit intermediate in the paper’s model requires full PDF access. no-fulltext-access

Regulatory arm	Sensor	Effector	TFEB site(s)	Net effect
mTORC1 (nutrient-replete)	Rag GTPases / Ragulator	mTOR kinase → 14-3-3 (docking at pSer211)	Ser142 (primary per Settembre 2012); Ser211 (primary 14-3-3 dock per Roczniak-Ferguson 2012); both rapamycin-resistant	Cytoplasmic retention
ERK2/MAPK (nutrient-replete)	Growth factors / nutrients	ERK2 kinase	Ser142 (per Settembre 2011)	Cytoplasmic retention (partial)
mTORC1 inactivation (starvation)	Rag GTPases OFF	Dephosphorylation of S142/S211	Ser142 + Ser211 dephospho	Nuclear translocation
Ca²+-calcineurin (lysosomal stress)	TRPML1/MCOLN1 → lysosomal Ca²+	Calcineurin (PP3CB)	Multiple sites dephospho (specific residues not confirmed from abstract)	Nuclear translocation, mTOR-independent

AMPK connection

AMPK activates TFEB indirectly via mTORC1 suppression (AMPK phosphorylates Raptor and TSC2 to inhibit mTORC1), thus relieving the cytoplasmic retention of TFEB. Whether AMPK phosphorylates TFEB directly is an open question. no-mechanism — direct AMPK-TFEB phosphorylation has been proposed in some contexts but is not well established in the primary literature; the dominant pathway is indirect (via mTORC1).

Active TFEB — transcriptional outputs

Once in the nucleus, TFEB binds CLEAR elements and drives expression of the autophagy–lysosomal gene program. Downstream functional consequences:

Autophagosome formation — via ULK1, BECN1, ATG7, LC3 upregulation
Autophagosome–lysosome fusion — via LAMP1, LAMP2 upregulation
Lysosomal biogenesis — increased lysosome number and size
Lysosomal acidification — via v-ATPase subunit upregulation
Lipophagy — lipid droplet autophagy activated via lipase and lipophagy receptor upregulation ²
Lysosomal exocytosis — TFEB also promotes secretory lysosome fusion with the plasma membrane, a mechanism cells use to expel indigestible aggregates

This feedback loop is self-reinforcing: lysosomal degradation of autophagic cargo releases amino acids that can re-activate mTORC1 (via Rag GTPases sensing intra-lysosomal amino acids), which then re-phosphorylates TFEB — a homeostatic cycle coupling nutrient sensing to lysosomal capacity.

TFEB in aging

Decline of TFEB activity in aged tissues

TFEB target gene expression — lysosomal and autophagy genes — declines with age in multiple tissues, consistent with reduced TFEB activity contributing to the age-related autophagy deficit. unsourced — the direct measurement of TFEB nuclear occupancy and CLEAR-network expression in aged human tissues lacks a single comprehensive primary citation; multiple studies report individual target gene declines. A genome-wide ChIP-seq aging dataset in human tissue is lacking.

TFEB overexpression rescues aging phenotypes in mice

Genetic overexpression of TFEB in mouse liver results in enhanced autophagy flux, reduced lipid accumulation, and improved metabolic parameters. Tissue-specific TFEB overexpression in the context of aging (muscle, brain, liver) has shown proof-of-concept benefits in mouse models. needs-human-replication — all mouse overexpression data; no equivalent human genetic evidence.

Dimension	Status	Notes
Pathway conserved in humans?	yes	mTORC1-TFEB-14-3-3 axis and CLEAR elements are fully conserved in human; TFEB target gene promoter motifs identified in human genome by Sardiello 2009
Phenotype conserved in humans?	partial	TFEB loss-of-function associated with lysosomal storage diseases (Birt-Hogg-Dubé via FLCN interaction); TFEB amplification seen in renal cell carcinoma
Replicated in humans?	no	No human aging intervention trial directly targeting TFEB

C. elegans ortholog HLH-30 — longevity function

The TFEB ortholog in C. elegans is HLH-30. Lapierre et al. 2013 showed that HLH-30 is required for the lifespan extension conferred by six mechanistically distinct longevity models in C. elegans ⁶. Specifically:

HLH-30 nuclear localization increases in all six longevity models tested
hlh-30 is essential for extended lifespan in six mechanistically distinct longevity paradigms (the abstract specifies six; the eat-2 DR model and daf-2 IIS-reduced model are among them but the full set of six covers additional pathways)
HLH-30 activates autophagy gene expression in a manner analogous to mammalian TFEB
Overexpression of HLH-30 extends lifespan in C. elegans ⁶
Nuclear TFEB levels are also augmented in mouse liver under dietary restriction, linking the worm and mammalian findings ⁶

This establishes TFEB/HLH-30 as a mechanistic convergence point downstream of multiple canonical longevity pathways — not merely a correlate of autophagy but causally required for the lifespan benefits of diverse longevity interventions. The wiki’s prior description (eat-2 and daf-2 only) understated the scope — the paper tested six models. needs-human-replication — the mouse liver dietary restriction finding is correlative (nuclear TFEB levels), not interventional.

Dimension	Status	Notes
Pathway conserved in humans?	yes	TFEB is the direct mammalian ortholog; CLEAR element binding is conserved
Phenotype conserved in humans?	unknown	Longevity benefit of TFEB in human aging tissue not tested
Replicated in humans?	no	Worm-only data needs-human-replication

Pathway membership

autophagy — TFEB is the master transcriptional activator of the autophagy gene program
mtor — mTORC1 phosphorylates and retains TFEB; inactivation of mTORC1 is the dominant TFEB-activating signal
ampk — AMPK activates TFEB indirectly via mTORC1 suppression
ulk1 — ULK1 is a direct TFEB transcriptional target (CLEAR network); TFEB–ULK1 axis provides transcriptional amplification of autophagy induction

Pharmacological relevance

No clinical-stage TFEB-activating compound exists in aging specifically. Relevant pharmacology:

Rapamycin / rapalogs — mTORC1 inhibition → TFEB activation (partial; rapamycin is allosteric, less effective than catalytic inhibitors for TFEB)
Torin1 — catalytic mTOR inhibitor; potent TFEB activator in vitro; not clinical
Metformin — AMPK activator → indirect TFEB activation via mTORC1 suppression
TRPML1 (mucolipin-1) agonists — ML-SA1 and related compounds activate the Ca²+-calcineurin-TFEB arm; preclinical only
Trehalose — proposed to activate TFEB in an mTOR-independent manner; mechanism disputed no-mechanism

Known interactors

mtor-complex-1 — phosphorylates TFEB at Ser142 (primary kinase assay site, Settembre 2012) and Ser211 (additional site, Settembre 2012; primary 14-3-3 dock, Roczniak-Ferguson 2012); both are rapamycin-resistant phosphosites; central negative regulator
14-3-3-proteins — bind phospho-Ser211 (per Roczniak-Ferguson 2012), sequester TFEB in cytosol
calcineurin — dephosphorylates TFEB; activated by lysosomal Ca²+ release via TRPML1
rag-gtpases — recruit mTORC1 to lysosomal surface; Rag GTPase activity gates the nutrient-sensing input to TFEB
tfe3 — paralog with largely overlapping CLEAR-network targets; TFE3 and TFEB show partial functional redundancy in some tissues

Limitations and gaps

CLEAR network gene count — The frequently cited “~500” figure refers to bioinformatic candidates from Sardiello 2009 (471 predicted per prior extraction); the experimentally confirmed core set is smaller (~96 per prior extraction). These figures are NOT in the Sardiello 2009 abstract and the full PDF is closed-access — they could not be verified in this pass. A genome-wide ChIP-seq characterization (Palmieri 2011, PMID 21358634) should be cited for confirmed targets. unsourced no-fulltext-access
Calmodulin as TRPML1→calcineurin intermediate — The wiki body states “lysosomal Ca²+ is released via mucolipin-1 (TRPML1) → calmodulin → calcineurin.” The Medina 2015 abstract only states MCOLN1 activates calcineurin directly; calmodulin as the intermediate Ca²+-sensor is not in the abstract. This mechanistic detail requires verification against the Medina 2015 full PDF (not_oa). no-fulltext-access
Lapierre 2013 six longevity models — The paper demonstrates HLH-30 is required for six mechanistically distinct longevity models; the original wiki extraction stated only eat-2 (DR) and daf-2 (IIS). The other four models are not specified in the abstract. The full paper is needed to enumerate all six. no-fulltext-access (download failed)
ERK2 vs mTORC1 as primary regulator — Settembre 2011 identifies ERK2 as the primary TFEB kinase (S142), with rapamycin having minimal effect; Settembre 2012 establishes mTORC1 as primary at S142/S211 with rapamycin-resistant sites. These are not contradictory (both phosphorylate S142) but the relative contributions of ERK2 vs mTORC1 to TFEB regulation in different physiological contexts remain incompletely resolved.
Human aging tissue data — Direct measurement of TFEB nuclear localization or ChIP-seq occupancy in aged vs. young human tissue is lacking. Indirect evidence (age-related decline in lysosomal gene expression) exists in databases but has not been systematically attributed to TFEB in a primary study. needs-human-replication
AMPK → TFEB direct phosphorylation — Whether AMPK directly phosphorylates TFEB (vs. acting only via mTORC1) is unresolved. no-mechanism
Therapeutic window — Chronic TFEB overactivation risks aberrant lysosomal exocytosis, inflammation (via TFEB regulation of immune gene expression), and — given TFEB amplification in renal cell carcinoma — potential oncogenic effects at supraphysiological levels. Dose-response for aging benefit is not characterized in any mammalian system. dose-response-unclear
GenAge entry — A GenAge ID for TFEB is not confirmed in this extraction; check https://genomics.senescence.info/genes/ for a current entry. needs-canonical-id

Footnotes

doi:10.1126/science.1174447 · Sardiello M et al. (Science, 2009) · in-vitro + bioinformatic · model: cultured cells (specific cell lines not confirmed from abstract; paper is not_oa) · most lysosomal genes show coordinated transcriptional behavior regulated by TFEB; TFEB overexpression induces lysosomal biogenesis; TFEB activation clears pathogenic proteins including mutant huntingtin; identified CLEAR element and TFEB as master lysosomal biogenesis regulator; 2434 citations · note: the “471 predicted / 96 confirmed” gene-count figures cited in body are not in the abstract and could not be verified (no PDF access); these figures are from prior wiki extraction and remain unsourced pending full-text access · no-fulltext-access ↩ ↩²
doi:10.1126/science.1204592 · Settembre C et al. (Science, 2011) · in-vivo + in-vitro · model: HeLa, COS7, MEFs, mouse liver (AAV-Tfeb and conditional Tcfeb transgenic) · TFEB coordinates autophagy and lysosomal biogenesis via a shared transcriptional program; ERK2 (MAPK) phosphorylates TFEB at Ser142 to control nuclear localization — rapamycin had minimal effect, Pearson r=0.42 between TFEB overexpression and starvation-induced autophagy gene expression (P=0.001, n=51 autophagy genes); 3131 citations ↩ ↩² ↩³
doi:10.1038/emboj.2012.32 · Settembre C et al. (EMBO J, 2012) · in-vitro + in-vivo · model: HeLa, HEK-293T, MEFs (Sin1−/− and TSC2−/−), mouse primary hepatocytes (Tcfeb conditional KO) · mTORC1 phosphorylates TFEB: primary site Ser142 (confirmed by phospho-antibody and in-vitro kinase assay); additional site Ser211 (identified by S211A mutagenesis causing constitutive nuclear TFEB); Rag GTPases necessary and sufficient for mTORC1-mediated TFEB retention; Torin1 EC50 ≈ 148 nM for TFEB nuclear translocation vs rapamycin EC50 ≈ 104,000 nM (rapamycin-resistant phosphosites); lysosome-to-nucleus sensing mechanism; 1865 citations ↩ ↩² ↩³
doi:10.1126/scisignal.2002790 · Roczniak-Ferguson A et al. (Sci Signal, 2012) · in-vitro · model: not confirmed from full text (paper is not_oa; abstract verified) · mTOR-dependent phosphorylation of TFEB at Ser211 → 14-3-3 binding → cytoplasmic retention; reduced mTOR-dependent phosphorylation upon lysosomal dysfunction → TFEB nuclear translocation → lysosomal biogenesis genes; MITF and TFE3 similarly regulated; 1313 citations · no-fulltext-access ↩ ↩²
doi:10.1038/ncb3114 · Medina DL et al. (Nat Cell Biol, 2015) · in-vitro + in-vivo · model: not confirmed from full text (paper is not_oa; abstract verified) · lysosomal Ca²+ release via mucolipin 1 (MCOLN1/TRPML1) → calcineurin activation → calcineurin dephosphorylates TFEB → nuclear translocation; genetic and pharmacological calcineurin inhibition suppressed TFEB activity during starvation and exercise; MCOLN1-mediated calcineurin activation required for autophagy and lysosomal biogenesis induction via TFEB; identifies lysosome as signalling hub; 1335 citations · note: calmodulin as intermediate (cited in wiki body) not confirmed from abstract alone — requires full PDF · no-fulltext-access ↩ ↩² ↩³
doi:10.1038/ncomms3267 · Lapierre LR et al. (Nat Commun, 2013) · in-vivo · model: Caenorhabditis elegans + mouse liver (dietary restriction correlate) · HLH-30 (TFEB ortholog) is essential for extended lifespan in six mechanistically distinct longevity models (not only eat-2/DR and daf-2/IIS as previously described); HLH-30 overexpression extends lifespan; nuclear HLH-30 increases in all six longevity models; nuclear TFEB also elevated in mouse liver under dietary restriction; 524 citations · note: PDF download failed (bronze OA but URL filter excluded); abstract verified via PubMed PMID 23925298 ↩ ↩² ↩³

🧬 Aging Wiki

Explorer

tfeb